Optimer Pharmaceuticals News

Main Category: Infectious Diseases / Bacteria / Viruses Also Included In: Clinical Trials / Drug Trials ; Pharma Industry / Biotech Industry Article Date: 13 Nov 2009 - 1:00 PST Optimer Pharmaceuticals, Inc.

Optimer Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2009.

Scope of the reports Each Life Science AnalyticsA' Pipeline Report provides the user with real detail on a companyA's pipeline.

Optimer Pharmaceuticals, Inc. today announced the presentation of new data from fidaxomicin's North American phase 3 study at the 47th Annual Meeting of the Infectious Diseases Society of America in Philadelphia, PA.

BUYINS.NET, www.buyins.net, has reviewed the NYSE, NASDAQ, BX, CHX and NSX Daily Short Volume Report for Tuesday, September 29th, 2009 and come to the following statistical conclusions.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Optimer Pharmaceuticals, Inc. today announced that new data highlighting fidaxomicin's lower CDI recurrence rates and reduced risk of vancomycin-resistant enterococci acquisition from Optimer's North American phase 3 study were presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy in San Francisco.

Optimer Pharmaceuticals, Inc. today announced the presentation of results from its second prulifloxacin Phase 3 clinical study for the treatment of infectious diarrhea in travelers, by clinical investigator Robert Steffen, M.D., at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy in San Francisco.

SAN DIEGO, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc.

Optimer Pharmaceuticals recently announced results from the phase III clinical study of fidaxomicin in patients with Clostridium difficile-associated diarrhea at the Digestive Disease Week 2009 conference in Chicago.

Optimer Pharmaceuticals, Inc. announced that additional results from its North American Phase 3 clinical study of fidaxomicin in patients with Clostridium difficile infection were presented today by clinical investigator, Mark A. Miller, M.D., at the Digestive Disease Week 2009 conference in Chicago.

Shares of San Diego-based Optimer Pharmaceuticals Inc . fell Monday as several analysts expressed concern over study results from the company's developing gastrointestinal infection drug, Fidaxomicin.

Companies mentioned in this article: Optimer Pharmaceuticals, Inc. Positive data from subgroup analysis presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases meeting in Helsinki , Finland SAN DIEGO , May 17 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc.

Cempra Pharmaceuticals Inc. raised $46 million in a Series C financing to continue clinical trials with the two antibiotic programs it licensed three years ago from Optimer Pharmaceuticals Inc.